Literature DB >> 32967901

Comparison of Agar Dilution to Broth Microdilution for Testing In Vitro Activity of Cefiderocol against Gram-Negative Bacilli.

Mariana Albano1, Melissa J Karau1, Audrey N Schuetz1, Robin Patel2,3.   

Abstract

Cefiderocol (CFDC) is a siderophore cephalosporin with activity against Gram-negative bacterial species that are resistant to carbapenems and other drugs. The MICs of CFDC were determined for 610 Gram-negative bacilli, including 302 multinational Enterobacterales isolates with characterized mechanisms of beta-lactam resistance, 180 clinical isolates from the Mayo Clinic and Mayo Clinic Laboratories not characterized for specific resistance mechanisms, and 128 isolates with CFDC MICs of ≥8 μg/ml obtained from International Health Management Associates, Inc. (IHMA, Schaumburg, IL). Broth microdilution using standard cation-adjusted Mueller-Hinton broth (BMD) and iron-depleted cation-adjusted Mueller-Hinton broth (ID-BMD), and agar dilution (AD) using standard Mueller-Hinton agar were performed according to Clinical and Laboratory Standards Institute (CLSI) guidelines. MICs were interpreted according to the investigational CLSI, FDA, and EUCAST breakpoints, and results were compared. MICs inhibiting 50 and 90% of organisms (MIC50 and MIC90, respectively), essential agreement (EA), categorical agreement (CA), and error of different types were determined. Results showed considerable discordance between AD and ID-BMD. CFDC showed low EA and CA rates and high error rates for AD in comparison to ID-BMD. Overall, this study does not support use of standard AD for determining CFDC MICs.
Copyright © 2020 Albano et al.

Entities:  

Keywords:  Enterobacteraleszzm321990; Gram-negative bacilli; Gram-negative bacteria; agar dilution; broth microdilution; cefiderocol

Year:  2020        PMID: 32967901      PMCID: PMC7771473          DOI: 10.1128/JCM.00966-20

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  8 in total

Review 1.  Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.

Authors:  Chuanhai Wang; Deqing Yang; Yifan Wang; Wentao Ni
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

Review 2.  Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2021-08-24       Impact factor: 9.546

3.  Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing.

Authors:  Erika Matuschek; Christopher Longshaw; Miki Takemura; Yoshinori Yamano; Gunnar Kahlmeter
Journal:  J Antimicrob Chemother       Date:  2022-05-29       Impact factor: 5.758

Review 4.  Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales.

Authors:  Xing Tan; Hwan Seung Kim; Kimberly Baugh; Yanqin Huang; Neeraja Kadiyala; Marisol Wences; Nidhi Singh; Eric Wenzler; Zackery P Bulman
Journal:  Infect Drug Resist       Date:  2021-01-18       Impact factor: 4.003

Review 5.  Treatment of Severe Infections Due to Metallo-Betalactamases Enterobacterales in Critically Ill Patients.

Authors:  Jean-François Timsit; Paul-Henri Wicky; Etienne de Montmollin
Journal:  Antibiotics (Basel)       Date:  2022-01-24

6.  Comment on: Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance.

Authors:  Christopher M Longshaw; Anne Santerre Henriksen; Christine Slover; Yoshinori Yamano; J Andreas Karas
Journal:  J Antimicrob Chemother       Date:  2022-09-30       Impact factor: 5.758

7.  Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii.

Authors:  Laurent Poirel; Mustafa Sadek; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2021-07-12       Impact factor: 5.191

Review 8.  Cefiderocol: An Overview of Its in-vitro and in-vivo Activity and Underlying Resistant Mechanisms.

Authors:  Jiahui Yao; Jin Wang; Mengli Chen; Yun Cai
Journal:  Front Med (Lausanne)       Date:  2021-12-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.